Glofitamab plus chemo for Burkitt and double hit lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests if adding a new targeted drug called glofitamab to standard chemotherapy works better than chemo alone for people with Burkitt lymphoma or double hit lymphoma. It may be a good option if you are newly diagnosed or if your lymphoma has come back after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either Burkitt lymphoma, double hit lymphoma, or relapsed/refractory high-grade B-cell lymphoma
- You may have had no prior treatment, or only one cycle of chemotherapy before joining (unless you have relapsed disease)
- You must be at least 18 years old
- Your blood counts, kidney function, and liver function must be within acceptable ranges (your doctor can check these)
- You must not have serious heart disease, active infections, certain autoimmune diseases, or brain involvement from the lymphoma
- Women who could become pregnant need a negative pregnancy test and must not be breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This study tests a new drug called glofitamab combined with standard chemotherapy (RCHOP) for people with HIV who have been newly diagnosed with a type of blood cancer called large B-cell lymphoma. The goal is to see if adding glofitamab helps fight the cancer better than chemotherapy alone.
This trial adds glofitamab, a new targeted drug, to standard chemotherapy for people with untreated mantle cell lymphoma. The goal is to see if the combination works better than chemo alone.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests combining radiation therapy with a drug called glofitamab (a type of immunotherapy) for patients whose diffuse large B-cell lymphoma (DLBCL) has returned or stopped responding to previous treatments. The goal is to see if adding radiation to this newer drug helps control the cancer better.
Hear when a new Recurrent Burkitt Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.